The FDA has issued a CRL to Lexicon regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for T1D and CKD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback